Key points from article :
PulseSight Therapeutics is developing minimally invasive, non-viral gene therapies for sight conditions.
Their two lead candidates target different forms of age-related macular degeneration (AMD).
PST-809 targets wet AMD and aims to be more effective and require less frequent treatment than current options.
PST-611 targets dry AMD and geographic atrophy and may also benefit patients with other retinal diseases.
Therapies transferred to the eye using electro-transfection to get the therapeutic proteins to the ciliary muscle in DNA plasmids.
Technology has been tested safely in humans with another eye condition, chronic noninfectious uveitis.
Currently raising Series A funding to advance their gene therapy candidates into clinical trials.
